MARKET

ICAD

ICAD

Icad Inc
NASDAQ
1.610
+0.010
+0.63%
After Hours: 1.530 -0.08 -4.97% 18:49 03/28 EDT
OPEN
1.600
PREV CLOSE
1.600
HIGH
1.660
LOW
1.530
VOLUME
74.07K
TURNOVER
0
52 WEEK HIGH
3.970
52 WEEK LOW
1.050
MARKET CAP
42.43M
P/E (TTM)
-4.0749
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ICAD last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at ICAD last week (0311-0315)?
Weekly Report · 03/18 12:16
Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
Analysts have issued new ratings on iCAD, Mustang Bio and Cerus. BTIG maintained a Buy rating on the Healthcare sector with a price target of $3.00 for iCad. In a report released yesterday, BTIG also maintained a Hold rating on Cerus and a Buy on Mustang Bio.
TipRanks · 03/13 10:10
icad: Q4 Earnings Insights
Icad reported its Q4 earnings of $-0.02 on March 12. The company's revenue was down $1.75 million from the same period last year. Icad beat estimates by 60.0%. The company is expected to announce its earnings Tuesday.
Benzinga · 03/12 20:10
iCAD Non-GAAP EPS of -$0.02 beats by $0.03, revenue of $4.74M beats by $0.46M
Seeking Alpha · 03/12 20:02
BRIEF-iCAD, Inc. Q4 Gross Profit USD 4.3 Million
Reuters · 03/12 20:01
Press Release: iCAD Announces Fiscal Fourth -4-
Starting in the third quarter of 2023, the Company began reporting Annual Recurring Revenue ("ARR") with each quarterly earnings announcement. The Company excludes litigation costs from its non-GAAP measures because it does not have a direct correlation to future business operations. The Company's annualized subscription revenue is not a replacement for GAAP revenue.
Dow Jones · 03/12 20:01
Press Release: iCAD Announces Fiscal Fourth -3-
Comprehensive net loss for the three months ended December 31, 2017 was $1,362. The company reported a net loss of $1.2 million. The Company's net loss per share was $0.08 for the quarter. For the year, the company lost $2.1 million. The company's total losses for the year were $3.1 billion.
Dow Jones · 03/12 20:01
More
About ICAD
iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Company’s Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.

Webull offers iCAD Inc stock information, including NASDAQ: ICAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ICAD stock methods without spending real money on the virtual paper trading platform.